Elekta's Nomination Committee's proposed Board of Directors to the Annual General Meeting
STOCKHOLM – The Nomination Committee of Elekta (EKTA-B.ST) proposes that the Annual General Meeting 2022 reelect Board members Laurent Leksell, who is also proposed to be reelected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Secher, Birgitta Stymne Göransson and Cecilia Wikström, and elect Kelly Londy as directors of the Board.
Kelly Londy has more than 30 years of experience in the medical technology industry and the healthcare sector. Among other roles, she has held senior management positions at companies such as Accuray, GE Healthcare and Philips Healthcare. Since 2021, she is CEO of the medical technology company Nuvo Group, and she is a board member of CMR Surgical Ltd. She has a bachelor’s degree in business and a degree in radiology, beginning her career as a radiographer at University of Michigan Health with a focus on women's health. A majority of Kelly’s career has been focused in oncology, surgery and imaging technology healthcare businesses to bring new innovations to market. Kelly Londy was born in 1966 and is a U.S. citizen.
The Nomination Committee's complete proposal will be published in connection with the convening of Elekta's Annual General Meeting 2022, held on 25 August 2022.
Prior to the Annual General Meeting 2022, the Nomination Committee consists of Laurent Leksell, (Chairman), with direct and indirect holdings; Jesper Bergström, Handelsbanken Fonder; Per Colleen, Fourth AP Fund; Filippa Gerstädt, Nordea Fonder; and Javiera Ragnartz, SEB Fonder. The chairman of the Nomination Committee is Laurent Leksell.
# # #
For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: Cecilia.Ketels@elekta.com
Time zone: Central European Time (CET)
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.